|
|
Article: NovaDx discovers osteoporosis drug opportunities; drug & diagnostic research results submitted to the American Society for Bone and Mineral Research.
- Article from:
- Business Wire
- Article date:
- April 22, 1997
CopyrightCOPYRIGHT 1997 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, British Columbia--(BW HealthWire)--April 22, 1997-- NovaDx International, Inc. (The "Company") (VSE: NVN) (NBB: NVDXF) is pleased to announce the discovery of new targets for osteoporosis drug development.
These proteins were identified by the Company's diagnostics research program using state of the art molecular biology techniques. These osteoporosis-related proteins have potential in both diagnostic and pharmaceutical roles and represent a new opportunity for the company.
NovaDx International, Inc. will form a new division in response to the significance of these discoveries and the large market potential for osteoporosis ...